title: The cost-effectiveness of screening and treatment for hepatitis C in prisons in England and Wales: a cost-utility analysis.
abstract: Prisoners have a high prevalence of hepatitis C virus (HCV) infection compared with the general population in England and Wales and in many locations throughout the world. This is because of large numbers of injecting drug users that engage in behaviours likely to transmit HCV being present within prison populations. It is, therefore, suggested that prison may be an appropriate location for HCV screening and treatment to be administered. Using cost-utility analysis, this study considers the costs and benefits of administering a single round of screening on reception into prison to all individuals followed by possible later screening in the community and comparing this to individuals who may only be tested and treated in the community at a later date. The cost/QALY of one round of prison testing and treatment was found to be 54,852 pounds sterling, although probabilistic sensitivity analysis showed extensive uncertainty about this estimate. One-way sensitivity analysis revealed the importance of the parameters describing the progression of chronic HCV and the discount rates. While the results presented here at baseline would suggest that screening and treatment for HCV in prisons is not cost-effective, these results are subject to much uncertainty. The importance of the rates describing the progression of chronic HCV on the cost-effectiveness of this intervention has been demonstrated and this suggests that future work should be undertaken to gain further insight into the rates that individuals progress to the later stages of chronic HCV infection.
authors.affiliation: Health Protection Agency, Centre for Infections, London, UK. Andrew.Sutton@warwick.ac.uk
authors.forename: A J
authors.initials: AJ
authors.lastname: Sutton
authors.forename: W J
authors.initials: WJ
authors.lastname: Edmunds
authors.forename: M J
authors.initials: MJ
authors.lastname: Sweeting
authors.forename: O N
authors.initials: ON
authors.lastname: Gill
mesh_terms: D000293:Adolescent; D000328:Adult; D003362:Cost-Benefit Analysis; D004739:England; D006526:Hepatitis C / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics*; D006801:Humans; D008875:Middle Aged; D011330:Prisons; D014852:Wales